Vardenafil (Levitra/Staxyn) FDA Approval History

Initial FDA Approval: Levitra Film-Coated Tablets (2003)

The FDA granted approval for vardenafil hydrochloride film-coated tablets under the brand name Levitra on August 19, 2003, via NDA 021400. Bayer Pharmaceuticals and GlaxoSmithKline co-marketed the drug in the United States, making vardenafil the second PDE5 inhibitor to reach the U.S. market after sildenafil (Viagra, approved 1998) and before tadalafil (Cialis, approved November 2003).

Approval rested on data from more than 30 clinical trials enrolling over 8,000 men with erectile dysfunction of varying severity and etiology. The key registration program included four randomized, double-blind, placebo-controlled trials conducted across North America and Europe. In one of these trials, Porst et al. (2003) randomized 580 men with ED to vardenafil 5 mg, 10 mg, 20 mg, or placebo for 12 weeks. The 20 mg dose produced successful intercourse attempts in 75% of encounters versus 41% for placebo (P<0.001), and scores on the International Index of Erectile Function (IIEF) erectile function domain rose by 8.8 points above baseline compared with 3.4 points for placebo [1]. The FDA reviewed these efficacy data alongside a safety database that, at the time of approval, included over 4,430 vardenafil-treated men and found an acceptable risk-benefit profile for all four approved strengths (2.5 mg, 5 mg, 10 mg, and 20 mg) [2].

The original label set the recommended starting dose at 10 mg taken approximately 60 minutes before sexual activity. Dose adjustment to 5 mg or 20 mg was permitted based on efficacy and tolerability, with a maximum dosing frequency of once daily [2].

Staxyn ODT Approval (2010)

On June 17, 2010, the FDA approved vardenafil orally disintegrating tablets (ODT) under the brand name Staxyn, NDA 022206. This formulation was designed to dissolve on the tongue without water, using a lyophilized matrix containing vardenafil hydrochloride trihydrate [3].

A critical pharmacokinetic distinction separates Staxyn from Levitra. The ODT formulation is not bioequivalent to the film-coated tablet. Peak plasma concentration (Cmax) is approximately 21% higher with the 10 mg ODT compared with the 10 mg film-coated tablet when both are taken in the fasted state [3]. Because of this difference, the FDA label explicitly states that Staxyn 10 mg and Levitra 10 mg should not be substituted for each other. Staxyn was approved at a single strength of 10 mg only, without the dose range available for Levitra.

The ODT formulation offered a clinical advantage for men who preferred not to swallow tablets or who wanted more discreet dosing. Its absorption profile is also altered by food: a high-fat meal reduces Staxyn's Cmax by approximately 35%, so the label recommends administration without water and without food [3].

Generic Vardenafil Entry

Patent protection for Levitra's core compound expired in stages. The primary U.S. patent (U.S. Patent No. 6,362,178) had an expiration date in 2018. Following Paragraph IV certification filings by multiple ANDA sponsors and subsequent litigation settlements, generic vardenafil film-coated tablets entered the U.S. market in 2018 [4].

Generic versions are rated as therapeutically equivalent (AB-rated) to Levitra by the FDA's Orange Book. Multiple manufacturers now supply generic vardenafil in 5 mg, 10 mg, and 20 mg strengths. The 2.5 mg strength has limited generic availability. Staxyn's ODT formulation has not seen generic entry as of 2026, partly because the lyophilized delivery technology carries separate patent and manufacturing complexity.

The price impact was substantial. Brand Levitra 20 mg carried an average wholesale price exceeding $60 per tablet before generic competition. Generic vardenafil 20 mg is available at roughly $2 to $8 per tablet depending on pharmacy and quantity, representing a reduction of 85% to 95% in per-dose cost [4].

Label Evolution and Safety Revisions

The vardenafil prescribing information has undergone several significant revisions since initial approval. Each revision reflects accumulating post-market safety data, new drug interaction findings, or alignment with class-wide PDE5 inhibitor labeling updates mandated by the FDA.

Nitrate Contraindication (2003, Original Label)

From the first approved label, vardenafil carried an absolute contraindication against concomitant use with organic nitrates in any form, whether scheduled or as-needed. PDE5 inhibition potentiates the hypotensive effects of nitric oxide donors, and the combination can produce severe, potentially fatal drops in blood pressure. The contraindication extends to amyl nitrite ("poppers"), which is sometimes used recreationally [2].

Alpha-Blocker Interaction Guidance (2004-2005)

The original label advised caution with alpha-adrenergic blockers but did not provide specific hemodynamic interaction data for all agents. Between 2004 and 2005, the label was revised to include interaction study results with tamsulosin and terazosin. Vardenafil 10 mg or 20 mg taken simultaneously with terazosin 5 mg or 10 mg produced clinically significant symptomatic hypotension in a substantial proportion of subjects. The updated label recommended that vardenafil should not be taken within 6 hours of an alpha-blocker dose, with the exception of tamsulosin 0.4 mg, which showed minimal additive blood pressure effect [2].

QT Prolongation Warning (2005)

A thorough QT/QTc study (required under ICH E14 guidance) found that vardenafil 10 mg produced a mean QTcF prolongation of approximately 8 milliseconds, and the supratherapeutic 80 mg dose prolonged QTcF by approximately 10 ms. These findings prompted the addition of specific QT prolongation language to Section 5 (Warnings and Precautions) of the label. The revision stated that vardenafil should be avoided in patients with congenital QT prolongation and in those taking Class IA (quinidine, procainamide) or Class III (amiodaril, sotalol) antiarrhythmic medications [2] [5].

This warning distinguishes vardenafil from sildenafil and tadalafil, neither of which carries a comparable QT-specific contraindication. The QT signal has influenced prescribing patterns in men with pre-existing cardiac conduction abnormalities or those on QT-prolonging medications.

Hearing Loss Advisory (2007)

In October 2007, the FDA issued a class-wide labeling revision for all PDE5 inhibitors (sildenafil, tadalafil, and vardenafil) to include warnings about sudden sensorineural hearing loss (SSNHL). The FDA's Adverse Event Reporting System (FAERS) had received 29 reports of sudden hearing decrease or loss temporally associated with PDE5 inhibitor use. While causality was not definitively established, the temporal association and biological plausibility (PDE5 expression in cochlear vasculature) warranted label inclusion. Patients are advised to stop the medication and seek medical attention if sudden hearing decrease occurs [6].

NAION Warning (2005, Expanded 2007)

Non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of acute vision loss, was added to PDE5 inhibitor labels beginning in 2005. Post-market reports to the FDA described cases of NAION occurring within 24 hours of PDE5 inhibitor use. The vardenafil label warns that patients with a history of NAION in one eye are at higher risk of recurrence and that the drug should be used with caution in this population. An FDA-commissioned epidemiologic review estimated the background rate of NAION at approximately 2.5 to 11.8 per 100,000 men aged 50 and older per year, making attribution to drug exposure difficult at an individual level [7].

Priapism and Sickle Cell Interactions (Ongoing Updates)

The label has consistently warned about the risk of priapism (erection lasting more than 4 hours) with all PDE5 inhibitors. Specific language regarding increased susceptibility in men with sickle cell disease, multiple myeloma, or leukemia was present from the original approval and has been retained through all revisions [2].

Post-Market Surveillance and Real-World Safety Data

Since approval, vardenafil has accumulated over two decades of real-world safety data. The FDA Sentinel System, which conducts active post-market surveillance using electronic health care data from over 100 million patients, has monitored PDE5 inhibitor safety signals including cardiovascular events, melanoma risk, and priapism incidence [8].

A large retrospective cohort study published in JAMA Internal Medicine (2014) examined cardiovascular outcomes among men prescribed PDE5 inhibitors, including vardenafil. Among 93,983 men with a new PDE5 inhibitor prescription, the study found no increased risk of myocardial infarction (adjusted hazard ratio 0.96 to 95% CI 0.83 to 1.11) and a possible reduction in all-cause mortality, although this finding required cautious interpretation due to healthy-user bias [9].

The European Medicines Agency (EMA) authorized vardenafil through its European Public Assessment Report (EPAR) process in March 2003, slightly preceding U.S. approval. Post-authorization safety updates from the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) have aligned with FDA actions, including the QT prolongation warning and the NAION/hearing loss advisories [10].

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins Medicine and a principal investigator in PDE5 inhibitor clinical research, has stated: "The PDE5 inhibitor class, including vardenafil, has one of the most extensively studied safety profiles of any drug class in urology. Two decades of post-market data have not revealed unexpected major risks beyond those identified in the original clinical trials" [11].

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy in men with hypogonadism notes that PDE5 inhibitors, including vardenafil, may be used as first-line pharmacotherapy for ED either alone or in combination with testosterone replacement, particularly in men whose erectile function does not fully recover with testosterone normalization alone [12].

Regulatory Comparison: Vardenafil vs. Other PDE5 Inhibitors

Vardenafil occupies a distinct regulatory position among the four FDA-approved PDE5 inhibitors. Sildenafil (approved 1998) was first to market and later gained a separate indication for pulmonary arterial hypertension (as Revatio). Tadalafil (approved 2003) received a supplemental approval in 2011 for daily dosing for benign prostatic hyperplasia (BPH). Avanafil (Stendra, approved 2012) was positioned for its rapid onset of action.

Vardenafil has never received supplemental indications beyond ED. Bayer explored a potential indication for premature ejaculation based on the drug's effect on ejaculatory latency, but this program did not advance to an NDA submission. The regulatory dossier remains focused on the original ED indication across both the film-coated and ODT formulations [2] [3].

One regulatory distinction worth noting: vardenafil is the only PDE5 inhibitor with a specific contraindication related to QT prolongation risk. The FDA label explicitly contraindicates vardenafil in patients taking Class IA or Class III antiarrhythmics, a restriction not present in the sildenafil, tadalafil, or avanafil labels [5].

Current Prescribing Considerations From the Label

The 2024 revised prescribing information for vardenafil film-coated tablets specifies the following key points for clinicians:

The recommended starting dose remains 10 mg taken orally approximately 60 minutes before sexual activity. Dose may be increased to 20 mg or decreased to 5 mg based on clinical response. Maximum recommended dosing frequency is once per day [2].

Dose adjustments are required in specific populations. Men aged 65 and older should start at 5 mg. Men taking moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) should not exceed 5 mg per 24 hours. Men taking potent CYP3A4 inhibitors (e.g., ketoconazole 400 mg daily, itraconazole 400 mg daily, ritonavir) should not exceed 2.5 mg per 72 hours [2].

Hepatic impairment (Child-Pugh B) requires a starting dose of 5 mg with a maximum of 10 mg. Vardenafil has not been studied in patients with severe hepatic impairment (Child-Pugh C) and is not recommended in that population. No dose adjustment is needed for mild to moderate renal impairment; the drug has not been evaluated in men on hemodialysis [2].

The label carries no FDA-required Risk Evaluation and Mitigation Strategy (REMS). It is classified as Pregnancy Category B (animal studies showed no fetal harm), although this classification is functionally irrelevant given the drug's approved use only in males [2].

The most commonly reported adverse reactions in clinical trials (incidence of 2% or greater and greater than placebo) were headache (15%), flushing (11%), rhinitis (9%), dyspepsia (4%), and sinusitis (3%). These rates were consistent across trials and remained stable in long-term open-label extension studies lasting up to 2 years [1] [2].

Vardenafil 10 mg film-coated tablets require a prescription in the United States, where all PDE5 inhibitors remain prescription-only. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) reclassified sildenafil to over-the-counter status in 2018, but no similar reclassification has occurred for vardenafil in any major regulatory jurisdiction as of May 2026.